Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions

  • Roxana Mehran
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • George Dangas
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Gary S. Mintz
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Alexandra J. Lansky
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Augusto D. Pichard
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Lowell F. Satler
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Kenneth M. Kent
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Gregg W. Stone
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.
  • Martin B. Leon
    From the Cardiovascular Research Foundation, New York and the Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC.

書誌事項

タイトル別名
  • Intravascular Ultrasound Study of 2256 Patients
公開日
2000-02-15
DOI
  • 10.1161/01.cir.101.6.604
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:italic>Background</jats:italic> —Elevation of serum creatine kinase MB fraction (CK-MB) after percutaneous coronary interventions has been associated with early and late mortality; however, the pathogenesis of CK-MB elevation is still unknown. We hypothesized that CK-MB elevation was related to atherosclerotic plaque burden as assessed by preintervention intravascular ultrasound (IVUS). </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> —We studied 2256 consecutive patients who underwent intervention of 2780 native coronary lesions and had complete high-quality preintervention IVUS imaging in the era before routine use of platelet glycoprotein IIb/IIIa inhibitors. Patients were divided into 3 groups: CK-MB within normal range (1675 patients; 2061 lesions); CK-MB elevation 1 to 5 times upper limit of normal (292 patients; 355 lesions); and CK-MB elevation ≥5 times upper limit of normal (289 patients; 364 lesions). Qualitative angiographic lesion morphology and quantitative analysis were similar among the 3 groups. On preintervention IVUS, progressively more reference segment and lesion site plaque burden and lesion site calcium occurred in the groups with CK-MB elevation. Positive remodeling was more common in lesions with CK-MB elevation. As levels of CK-MB increased, cross-sectional narrowing (percentage plaque burden) increased, both at the reference site (mean cross-sectional narrowing values were 45.1%, <49.3%, and <52.2% for normal CK-MB, 1 to 5 times upper limit of normal, and ≥5 times upper limit of normal groups, respectively; <jats:italic>P</jats:italic> =0.03) and at the lesion site (81.9%, <85.4%, and <87.1%, respectively; <jats:italic>P</jats:italic> =0.04). Multivariate analysis indicated that de novo lesions, atheroablative technique, plaque burden at the lesion and reference segments, and final minimal lumen diameter were independent predictors of CK-MB elevation. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —CK-MB elevation correlates with a greater atherosclerotic plaque burden. CK-MB elevation after intervention may be a marker of diffuse atherosclerotic disease or a consequence of catheter-based intervention in more diseased arteries or both. </jats:p>

収録刊行物

  • Circulation

    Circulation 101 (6), 604-610, 2000-02-15

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ